Most Read Articles
5 days ago
Girls with eosinophilic oesophagitis (EoE) who show initial response to directed therapy will tend to continue to respond well to treatment, a recent study has shown.
Pearl Toh, 3 days ago
Adding a LAMA* to the double combination therapy of ICS** plus LABA*** in a single inhaler improves lung function and reduces exacerbations in patients whose asthma is inadequately controlled with the combination treatment, according to the TRIMARAN and TRIGGER# studies presented at ERS 2019.
Elvira Manzano, 4 days ago
Final overall survival (OS) results from the double-blind phase III FLAURA study reinforce osimertinib as the standard frontline treatment for epidermal growth factor receptor-mutated (EGFRm) non–small cell lung cancer (NSCLC), say leading oncologists at ESMO 2019.
Tristan Manalac, 3 days ago
Babies born to mothers exposed to high levels of bisphenol A during pregnancy are at a greater risk of wheezing and poor lung function, according to a new study presented at the recently concluded International Congress of the European Respiratory Society (ERS 2019).

DOAC therapy prevents VTE recurrence, bleeding in patients with cancer

30 Sep 2018

Use of direct-acting oral anticoagulants (DOACs) in patients with cancer and venous thromboembolism (VTE) results in only two episodes of clinically significant bleeding and no episodes of recurrent VTE, according to the results of a single-centre, retrospective, observational study.

Of the 37 patients included, 12 were diagnosed with pulmonary embolism (PE), 21 with deep vein thrombosis (DVT), three with both DVT and PE, and one with DVT and superficial vein thrombosis. The most commonly used DOAC was apixaban (n=27).

None of the patients had a recurrent DVT or PE at 6 months. In addition, only two patients experienced adverse effects during treatment.

A previous study involving patients with active cancer and VTE showed rivaroxaban to have similar efficacy compared to enoxaparin and a vitamin K antagonist for the prevention of VTE recurrence and the reduction of major bleeding events. A head-to-head comparison of rivaroxaban with long-term low-molecular-weight heparin is needed in cancer patients. [Lancet Haematol 2014;1:e37-46]

To assess the use of DOAC in patients with cancer and VTE, the present study identified patients by a retrospective data extraction of those treated at Ochsner Medical Centre from 1 January 2013 through 31 December 2015.

Eligibility criteria for the review included age ≥18 years, a confirmed diagnosis of VTE and active or history of cancer, and treatment with dabigatran, apixaban, rivaroxaban or edoxaban for at least 6 months. The primary endpoints were the rate of VTE recurrence and incidence of bleeding at 6 months.

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Doctor - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
5 days ago
Girls with eosinophilic oesophagitis (EoE) who show initial response to directed therapy will tend to continue to respond well to treatment, a recent study has shown.
Pearl Toh, 3 days ago
Adding a LAMA* to the double combination therapy of ICS** plus LABA*** in a single inhaler improves lung function and reduces exacerbations in patients whose asthma is inadequately controlled with the combination treatment, according to the TRIMARAN and TRIGGER# studies presented at ERS 2019.
Elvira Manzano, 4 days ago
Final overall survival (OS) results from the double-blind phase III FLAURA study reinforce osimertinib as the standard frontline treatment for epidermal growth factor receptor-mutated (EGFRm) non–small cell lung cancer (NSCLC), say leading oncologists at ESMO 2019.
Tristan Manalac, 3 days ago
Babies born to mothers exposed to high levels of bisphenol A during pregnancy are at a greater risk of wheezing and poor lung function, according to a new study presented at the recently concluded International Congress of the European Respiratory Society (ERS 2019).